Welcome to Iconovo

Innovative and complete inhalation solutions for licensing

Iconovo’s long-standing expertise in developing innovative inhalation products and advanced capability in drug formulations guarantee complete, intuitive and cost-effective inhalation products.


  • Swedish Iconovo signs royalty-backed inhalation contract worth 2.8 million EUR

    Iconovo, a Swedish inhalation development company has signed a second major product development and licensing agreement ... Read more
  • Iconovo News 2017

    Iconovo has had a fantastic year. In May, we raised 2.5 million EUR to invest in our formulation development capability.... Read more
  • DDL

    Iconovo is proud to sponsor DDL this year again. We see DDL as the most important meeting for inhaled drug delivery in E... Read more
  • Iconovo has a new granted patent

    The Swedish Patent and Registration Office, PRV, has granted Iconovo's first ICOone patent. This is a key milestone show... Read more
  • New employees at Iconovo

    We welcome our two new associates; Maggie Adméus and Henrik Svedberg. Maggie as an Executive Assistant and Henrik as a ... Read more
  • New employee at Iconovo

    Mårten Appelgren has joined Iconovo as Director Business Development. Mårten has over 25 years experience from the inh... Read more
  • New employee at Iconovo

    We are very glad to announce that Vesna Åkerberg has joined Iconovo as Director of Pharmaceutical Development. Vesna wi... Read more
  • New Labs and offices at Medicon Village

    Iconovo has moved into new labs and offices at Medicon Village. We have now doubled our space and have several specializ... Read more
  • Investment in formulation development

    Iconovo has raised 2.3 million EUR to expand the in-house development capacity. We will now be able to offer a comprehen... Read more
  • Dry Powder Inhalers in London

    Iconovo CEO Dr. Orest Lastow will be giving a speach at Dry Powder Inhalers Conference 27-28 July in London. The title... Read more
Older news